Do I need a prescription for Nimodipine 30mg tablets?

Nimodipine 30mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Nimodipine 30mg tablets?

Nimodipine 30mg tablets is the generic name. It is available under brand names including: Nimotop 30mg tablets, Nimotop 30mg tablets, Nimotop 30mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Nimodipine 30mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

30mg

Oral

Nimodipine is a 1,4-dihydropyridine calcium channel blocker.

Active ingredients:

Nimodipine

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 02.06.02

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC C08CA06

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Nimodipine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Nimodipine

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Nimodipine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Nimodipine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

3 branded products available

3 productsShow details

3 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Nimodipine on the MHRA register

Nimotop 30mg tablets

Laboratoire X.O

Nimotop 30mg tablets

Dowelhurst Ltd

Discontinued

Nimotop 30mg tablets

Mawdsley-Brooks & Company Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£40.00indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

300 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Amlodipine 2.5mg tablets

Tablet

2.5mg

Same therapeutic group

Lacidipine 6mg tablets

Tablet

6mg

Same therapeutic group

Amlodipine 5mg/5ml oral suspension sugar free

Oral suspension

5mg/5ml

Same therapeutic group

Nimodipine 60mg/5ml oral suspension

Oral suspension

60mg/5ml

Same therapeutic group

Felodipine 2.5mg/5ml oral suspension

Oral suspension

2.5mg/5ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Nimodipine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(3)

Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (NG228)

NG228

NICE guideline

Updated Nov 2022

Migraine prophylaxis: flunarizine (ESUOM33)

ESUOM33

Evidence summary

Updated Sept 2014

Spinal injury: assessment and initial management (NG41)

NG41

NICE guideline

Updated Feb 2016

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Nimodipine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42215211000001109

dm+d ID

42215211000001109

VTM (Virtual Therapeutic Moiety)

776917002

VMP (Virtual Medicinal Product)

42215211000001109

BNF code

02060200

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C08CA06

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

30 found

Half-life

1.7-9 hours

Mechanism

Although the precise mechanism of action is not known, nimodipine blocks intrace…

Food interactions

2 warnings

Human targets

10 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

100%

In humans, nimodipine is rapidly absorbed after oral administration, and peak concentrations are generally attained within one hour.…

Half-life

1.7-9 hours

1.7-9 hours

Protein binding

95%

95% bound to plasma protein

Metabolism

Hepatic metabolism via CYP 3A4.

Elimination

Nimodipine is eliminated almost exclusively in the form of metabolites and less than 1% is recovered in the urine as unchanged drug.…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.

Properties:

solid

Avg. mass: 418.44 Da

View FDA drug label

DrugBank indication

For use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.

Also known as(62)

2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-methoxyethyl ester 5-isopropyl ester

isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate

isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate

Nimodipine

Nimodipino

Nimodipinum

CACH2

CACN2

Dosage forms(47)

Solution (Parenteral) — 10.00 mg

Injection (Intravenous) — 0.2 MG/ML

Solution (Parenteral) — 0.020 g

Solution — 10.000 mg

Tablet, film coated (Oral) — 30 MG

Injection, solution (Parenteral) — 0.2 MG/ML

Solution / drops (Oral) — 30 MG/0.75ML

Capsule (Oral) — 30 mg/1

Molecular properties(19)

Drug interactions(1315)

Known interactions with other medications. Always consult a healthcare professional.

Duloxetine

Major

DB00476

The risk or severity of orthostatic hypotension and syncope can be increased when Nimodipine is combined with Duloxetine.

Check this interaction

Levodopa

Major

DB01235

The risk or severity of hypotension and orthostatic hypotension can be increased when Nimodipine is combined with Levodopa.

Check this interaction

Risperidone

Moderate

DB00734

Nimodipine may increase the hypotensive activities of Risperidone.

Check this interaction

Ceritinib

Moderate

DB09063

Nimodipine may increase the bradycardic activities of Ceritinib.

Check this interaction

Ivabradine

Moderate

DB09083

Nimodipine may increase the bradycardic activities of Ivabradine.

Check this interaction

Ruxolitinib

Moderate

DB08877

Ruxolitinib may increase the bradycardic activities of Nimodipine.

Check this interaction

Alfuzosin

Moderate

DB00346

Alfuzosin may increase the hypotensive activities of Nimodipine.

Check this interaction

Amifostine

Moderate

DB01143

Nimodipine may increase the hypotensive activities of Amifostine.

Check this interaction

Diazoxide

Moderate

DB01119

Diazoxide may increase the hypotensive activities of Nimodipine.

Check this interaction

Methylphenidate

Moderate

DB00422

Methylphenidate may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Dexmethylphenidate

Moderate

DB06701

Dexmethylphenidate may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Obinutuzumab

Moderate

DB08935

Nimodipine may increase the hypotensive activities of Obinutuzumab.

Check this interaction

Pentoxifylline

Moderate

DB00806

Pentoxifylline may increase the hypotensive activities of Nimodipine.

Check this interaction

Rituximab

Moderate

DB00073

Nimodipine may increase the hypotensive activities of Rituximab.

Check this interaction

Desmopressin

Moderate

DB00035

Desmopressin may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Isoetharine

Moderate

DB00221

Isoetharine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Etomidate

Moderate

DB00292

Etomidate may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Zolmitriptan

Moderate

DB00315

Zolmitriptan may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Norepinephrine

Moderate

DB00368

Norepinephrine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Phenylpropanolamine

Moderate

DB00397

Phenylpropanolamine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Doxapram

Moderate

DB00561

Doxapram may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Metaraminol

Moderate

DB00610

Metaraminol may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Methoxamine

Moderate

DB00723

Methoxamine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Orciprenaline

Moderate

DB00816

Orciprenaline may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Phenmetrazine

Moderate

DB00830

Phenmetrazine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Dobutamine

Moderate

DB00841

Dobutamine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Pseudoephedrine

Moderate

DB00852

Pseudoephedrine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Ritodrine

Moderate

DB00867

Ritodrine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Bitolterol

Moderate

DB00901

Bitolterol may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Diethylpropion

Moderate

DB00937

Diethylpropion may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Naratriptan

Moderate

DB00952

Naratriptan may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Rizatriptan

Moderate

DB00953

Rizatriptan may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Dopamine

Moderate

DB00988

Dopamine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Frovatriptan

Moderate

DB00998

Frovatriptan may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Isoprenaline

Moderate

DB01064

Isoprenaline may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Arbutamine

Moderate

DB01102

Arbutamine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Lisdexamfetamine

Moderate

DB01255

Lisdexamfetamine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Fenoterol

Moderate

DB01288

Fenoterol may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Pirbuterol

Moderate

DB01291

Pirbuterol may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Ephedra sinica root

Moderate

DB01363

Ephedra sinica root may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Ephedrine

Moderate

DB01364

Ephedrine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Mephentermine

Moderate

DB01365

Mephentermine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Procaterol

Moderate

DB01366

Procaterol may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Clenbuterol

Moderate

DB01407

Clenbuterol may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Bambuterol

Moderate

DB01408

Bambuterol may decrease the antihypertensive activities of Nimodipine.

Check this interaction

MMDA

Moderate

DB01442

MMDA may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Midomafetamine

Moderate

DB01454

Midomafetamine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

2,5-Dimethoxy-4-ethylamphetamine

Moderate

DB01467

2,5-Dimethoxy-4-ethylamphetamine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

4-Methoxyamphetamine

Moderate

DB01472

4-Methoxyamphetamine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Brolamfetamine

Moderate

DB01484

4-Bromo-2,5-dimethoxyamphetamine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Showing 50 of 1315 interactions

Food & lifestyle interactions

Avoid Grapefruit

Avoid grapefruit products.

Advice

Take with or without food. Take consistently at the same time in regard to meals.

Toxicity & overdose

Symptoms of overdosage would be expected to be related to cardiovascular effects such as excessive peripheral vasodilation with marked systemic hypotension.

How it works

Mechanism of action

Although the precise mechanism of action is not known, nimodipine blocks intracellular influx of calcium through voltage-dependent and receptor-operated slow calcium channels across the membranes of myocardial, vascular smooth muscle, and neuronal cells. By specifically binding to L-type voltage-gated calcium channels, nimodipine inhibits the calcium ion transfer, resulting in the inhibition of vascular smooth muscle contraction. Evidence suggests that the dilation of small cerebral resistance vessels, with a resultant increase in collateral circulation, and/or a direct effect involving the prevention of calcium overload in neurons may be responsible for nimodipine's clinical effect in patients with subarachnoid hemorrhage.

Pharmacodynamics

Nimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured congenital aneurysms who are in good neurological condition post-ictus (e.g., Hunt and Hess Grades I-III). The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood brain barrier.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

In humans, nimodipine is rapidly absorbed after oral administration, and peak concentrations are generally attained within one hour. Bioavailability is 100% following intravenous administration and 3-30% following oral administration due to extensive first-pass metabolism.

Half-life

1.7-9 hours

Protein binding

95% bound to plasma protein

Metabolism

Hepatic metabolism via CYP 3A4.

Route of elimination

Nimodipine is eliminated almost exclusively in the form of metabolites and less than 1% is recovered in the urine as unchanged drug. Numerous metabolites, all of which are either inactive or considerably less active than the parent compound, have been identified.

Drug targets(10)

Proteins and enzymes this drug interacts with in the body

Voltage-dependent L-type calcium channel subunit alpha-1C

BE0000430

CACNA1C

inhibitor

Specific functionalpha-actinin binding

Cellular location

Cell membrane

General function & pharmacology

Pore-forming, alpha-1C subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents .
PMID:12181424 PMID:15454078 PMID:15863612 PMID:16299511 PMID:17224476 PMID:20953164 PMID:23677916 PMID:24728418 PMID:26253506 PMID:27218670 PMID:29078335 PMID:29742403 PMID:30023270 PMID:30172029 PMID:34163037 PMID:8099908

Mediates influx of calcium ions into the cytoplasm, and thereby triggers calcium release from the sarcoplasm (By similarity). Plays an important role in excitation-contraction coupling in the heart. Required for normal heart development and normal regulation of heart rhythm .
PMID:15454078 PMID:15863612 PMID:17224476 PMID:24728418 PMID:26253506

Required for normal contraction of smooth muscle cells in blood vessels and in the intestine.

Essential for normal blood pressure regulation via its role in the contraction of arterial smooth muscle cells .
PMID:28119464
Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group (Probable)

Voltage-dependent L-type calcium channel subunit alpha-1D

BE0002359

CACNA1D

inhibitor

Specific functionalpha-actinin binding

Cellular location

Membrane

General function & pharmacology

Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group.

They are blocked by dihydropyridines (DHP), phenylalkylamines, and by benzothiazepines

Voltage-dependent L-type calcium channel subunit alpha-1F

BE0002357

CACNA1F

inhibitor

Specific functionhigh voltage-gated calcium channel activity

Cellular location

Membrane

General function & pharmacology

Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group.

They are blocked by dihydropyridines (DHP), phenylalkylamines, and by benzothiazepines. Activates at more negative voltages and does not undergo calcium-dependent inactivation (CDI), due to incoming calcium ions, during depolarization

Voltage-dependent L-type calcium channel subunit alpha-1S

BE0002355

CACNA1S

inhibitor

Specific functioncalmodulin binding

Cellular location

Cell membrane, sarcolemma, T-tubule

General function & pharmacology

Pore-forming, alpha-1S subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents in skeletal muscle. Calcium channels containing the alpha-1S subunit play an important role in excitation-contraction coupling in skeletal muscle via their interaction with RYR1, which triggers Ca(2+) release from the sarcoplasmic reticulum and ultimately results in muscle contraction. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group

Voltage-dependent L-type calcium channel subunit beta-1

BE0000303

CACNB1

inhibitor

Specific functioncalcium channel regulator activity

Cellular location

Cell membrane, sarcolemma

General function & pharmacology

Regulatory subunit of L-type calcium channels .
PMID:1309651 PMID:15615847 PMID:8107964

Regulates the activity of L-type calcium channels that contain CACNA1A as pore-forming subunit (By similarity). Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit and increases the presence of the channel complex at the cell membrane .
PMID:15615847
Required for functional expression L-type calcium channels that contain CACNA1D as pore-forming subunit .
PMID:1309651
Regulates the activity of L-type calcium channels that contain CACNA1B as pore-forming subunit PMID:8107964

Metabolizing enzymes(1)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

Biological pathways(1)

Nimodipine Action Pathway

Involved compounds

ATP,Calcium,Magnesium cation,Nimodipine,Potassium cation

Scientific references(6)

Janjua N., Mayer S.A.

Cerebral vasospasm after subarachnoid hemorrhage.

Current Opinion in Critical Care

20039(2):113-119. doi: 10.1097/00075198-200304000-00006

PMID: 12657973 DOI: 10.1097/00075198-200304000-00006

Allen G.S., Ahn H.S., Preziosi T.J., Battye R., Boone S.C., Boone S.C., Chou S.N., Kelly D.L., Weir B.K., Crabbe R.A., Lavik P.J., Rosenbloom S.B., Dorsey F.C., Ingram C.R., Mellits D.E., Bertsch L.A., Boisvert D.P., Hundley M.B., Johnson R.K., Strom J.A., Transou C.R.

Cerebral Arterial Spasm – A Controlled Trial of Nimodipine in Patients with Subarachnoid Hemorrhage.

New England Journal of Medicine

1983308(11):619-624. doi: 10.1056/nejm198303173081103

PMID: 6338383 DOI: 10.1056/nejm198303173081103

Belfort M.A., Anthony J., Saade G.R., Allen JC Jr

A Comparison of Magnesium Sulfate and Nimodipine for the Prevention of Eclampsia.

New England Journal of Medicine

2003348(4):304-311. doi: 10.1056/nejmoa021180

PMID: 12540643 DOI: 10.1056/nejmoa021180

Kim J.H., Park I.S., Park K.B., Kang D.H., Hwang S.H.

Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage.

Journal Korean Neurosurg Society

2009 Sep46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30

PMID: 19844625 DOI: 10.3340/jkns.2009.46.3.239

Tomassoni D., Lanari A., Silvestrelli G., Traini E., Amenta F.

Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies.

Clinical Experimental Hypertens

2008 Nov30(8):744-66. doi: 10.1080/10641960802580232

PMID: 19021025 DOI: 10.1080/10641960802580232

Vergouwen M.D., Vermeulen M., Roos Y.B.

Effect of nimodipine on outcome in patients with traumatic subarachnoid haemorrhage: a systematic review.

The Lancet Neurology

20065(12):1029-1032. doi: 10.1016/s1474-4422(06)70582-8

PMID: 17110283 DOI: 10.1016/s1474-4422(06)70582-8

ATC classification(1 code)

ATC C08CA06

Affected organisms(1)

Humans and other mammals

International brands(1)

Experimental properties(2)

External resources(2)

RxList Drugs.com

Commercial products(24)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Nimodipine

DB00393

CAS number

66085-59-4

UNII (FDA)

57WA9QZ5WH

InChI Key (molecular fingerprint)

UIAGMCDKSXEBJQ-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

1910

ChEBI

7575

PubChem Compound

4497

PubChem Substance

46508497

KEGG Compound

C07267

KEGG Drug

D00438

ChemSpider

4341

BindingDB

50101971

PharmGKB

PA450633

Therapeutic Targets Database

DAP000306

IUPHAR

2523

Guide to Pharmacology

2523

Wikipedia

Nimodipine

ChEMBL

CHEMBL1428

RxCUI

7426

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1390

GenAtlas

CACNA1C

GeneCards

CACNA1C

GenBank Gene Database

M92270

IUPHAR

529

Guide to Pharmacology

529

UniProtKB

Q13936

UniProt Accession

CAC1C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1391

GenAtlas

CACNA1D

GeneCards

CACNA1D

GenBank Gene Database

M76558

GenBank Protein Database

179764

IUPHAR

530

Guide to Pharmacology

530

UniProtKB

Q01668

UniProt Accession

CAC1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1393

GenAtlas

CACNA1F

GeneCards

CACNA1F

GenBank Gene Database

AJ006216

GenBank Protein Database

3183953

IUPHAR

531

Guide to Pharmacology

531

UniProtKB

O60840

UniProt Accession

CAC1F_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1397

GenAtlas

CACNA1S

GeneCards

CACNA1S

GenBank Gene Database

U30707

GenBank Protein Database

1698403

IUPHAR

528

Guide to Pharmacology

528

UniProtKB

Q13698

UniProt Accession

CAC1S_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1401

GenAtlas

CACNB1

GeneCards

CACNB1

GenBank Gene Database

M92303

GenBank Protein Database

179806

UniProtKB

Q02641

UniProt Accession

CACB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1402

GenAtlas

CACNB2

GeneCards

CACNB2

GenBank Gene Database

S60415

GenBank Protein Database

300417

UniProtKB

Q08289

UniProt Accession

CACB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1403

GenAtlas

CACNB3

GeneCards

CACNB3

GenBank Gene Database

X76555

GenBank Protein Database

435135

UniProtKB

P54284

UniProt Accession

CACB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1404

GenAtlas

CACNB4

GeneCards

CACNB4

GenBank Gene Database

U95020

GenBank Protein Database

2058727

UniProtKB

O00305

UniProt Accession

CACB4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:7979

GenAtlas

NR3C2

GeneCards

NR3C2

GenBank Gene Database

M16801

GenBank Protein Database

307166

IUPHAR

626

Guide to Pharmacology

626

UniProtKB

P08235

UniProt Accession

MCR_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:348

GeneCards

AHR

GenBank Gene Database

D16354

GenBank Protein Database

533324

Guide to Pharmacology

2951

UniProtKB

P35869

UniProt Accession

AHR_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

International reference pricing

3 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $9.69/capsule

To $952.07/box

Nimodipine 30 mg capsule

$9.69/capsule

Nimotop 30 mg capsule

$9.87/capsule

NiMODipine 100 30 mg capsule Box

$952.07/box

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

Patent information

8 active patents, 2 expired

10342787

United States

Approved 9 Jul 2019 · Expires 16 Apr 2038

12 years

10576070

United States

Approved 3 Mar 2020 · Expires 16 Apr 2038

12 years

11207306

United States

Approved 28 Dec 2021 · Expires 16 Apr 2038

12 years

11413277

United States

Approved 16 Aug 2022 · Expires 16 Apr 2038

12 years

11517563

United States

Approved 6 Dec 2022 · Expires 16 Apr 2038

12 years

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Nimodipine 30mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(3)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
12

Chemical identifiers

Nimodipine

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Nimodipine 30mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(3)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science12

Chemical identifiers

Nimodipine

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Deep science
12